CAS 67869-62-9: gly-pro-arg-pro acetate

H-Gly-Pro-Arg-Pro-OH is a sealant that has been shown to be effective in the treatment of bowel disease. It is a calcium binding compound that can be administered topically or systemically. H-Gly-Pro-Arg-Pro-OH has clinical relevance in vivo with human beings and exhibits ATP levels that are similar to those found in normal tissue. The surface glycoprotein of this compound has been shown to have an affinity for epidermal growth factor, which may play a role in inflammatory bowel disease. HGPAROH is activated by fibrinogen, which leads to its bound form being recognized by monoclonal antibody as well as the human serum proteins (e.g., albumin).

GPRP (Gly-Pro-Arg-Pro) is a fibrin polymerization inhibitor.

Fibrinolysis Inhibiting Factor is a surface glycoprotein that belongs to the group of human serum proteins. It has been shown to be involved in the pathogenesis of bowel diseases and is a target for dextran sulfate. Fibrinolysis inhibiting factor binds to the surfaces of cells and blocks blood coagulation by interfering with the conversion of fibrinogen into fibrin. The protein also binds calcium ions and prevents them from being deposited on cell surfaces, thereby preventing inflammatory reactions such as inflammation of the bowel. Fibrinolysis inhibiting factor has been shown to activate monoclonal antibodies in vitro, which may explain its effect on inflammatory bowel disease.

GPRP (H-2935) inhibits fibrinogen/thrombin clotting, though it is less active than its C-terminal amide GPRP-NH₂.